Kuva Intends to Commence Tender Offer for Lisata Therapeutics by May 29, 2026

About this update from Lisata Therapeutics, Inc.

Kuva reaffirms commitment to previously announced acquisition terms HOUSTON, TX, UNITED STATES, May 4, 2026 /EINPresswire.com/ -- On May 3, 2026, Kuva Labs, Inc. (“Kuva” or “Parent”) and Lisata Therapeutics, Inc. (“Lisata”) (Nasdaq:LSTA), together with Kuva’s wholly owned subsidiary Kuva Acquisition Corp. (“Kuva Acquisition”), entered into an amendment and waiver (the “Amendment and Waiver”) to the previously announced Agreement and Plan of Merger, dated as of March 6, 2026, by and among Kuva, Kuva Acquisition and Lisata (the “Merger Agreement”). Pursuant to the Amendment and Waiver, Kuva and Lisata, agreed to extend the date by which Kuva Acquisition is obligated to commence the tender offer for all of the outstanding shares of common stock of Lisata (the “Offer”) from April 13, 2026 to May 29, 2026, or such other date as may be agreed to between the Company and Kuva. Kuva intends to commence the Offer to acquire Lisata on or before May 29, 2026, on the terms set forth in the Merger Agreement. Pursuant to the Amendment and Waiver, Kuva has agreed to cover certain of Lisata’s operating expenses until the Offer is commenced. “We remain committed to completing this transaction,” said Mark Land, Chief Executive Officer of Kuva. About Kuva Kuva is a clinical bioscience company developing the proprietary NanoMark direct MR imaging platform. Kuva was founded in 2019, after its founders experienced tragic losses in cancer cases which could have been presented with better tools. In partnership with leading oncology research organizations Kuva is seeking to transform the way cancer is seen and ultimately treated. This technology enables the selective and unambiguous imaging of solid tumors with the highest contrast and spatial resolution without the use of ionizing radiation. This information speeds both accurate diagnosis and treatment - delivering better and quicker clinical intervention and better overall outcomes. For more information, please visit www.kuvalabs.com. Additional Information and Where to Find It The tender offer referred to in this communication has not yet commenced. This communication is for informational purposes only and is neither an offer to purchase nor a solicitation of an offer to sell shares, nor is it a substitute for the tender offer materials that Parent and Purchaser will file with the SEC upon commencement of the tender offer, if c...

View stock analysis, news, and events for Lisata Therapeutics, Inc.